[1] Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol (2010);55:558-65.
[2] Laufs U (2006): Pathophysiologie der koronaren Herzerkrankung. (Hrsg.):
Klinische Pathophysiologie. 9. Aufl.; S. 523-545. Stuttgart: Thieme.
[3] Rutsch W, Gliech V, Dubel HP, Borges A, Theres H, Laule M et al. [Standards in interventional therapy of coronary artery disease]. Herz (2002);27:481-501.
[4] van Buuren F, Horstkotte D. [21st report about the statistics of the heart catheterization laboratory in the German Federal Republic. Results of the joint inquiry of the Commission for Clinical Cardiology and of the Working Groups for Interventional Cardiology and Angiology of the German Society for Cardiology and Circulatory Research in the year 2004]. Clin Res Cardiol (2006);95:383-7.
[5] Grech ED. ABC of interventional cardiology: percutaneous coronary intervention.
II: the procedure. BMJ (2003);326:1137-40.
[6] Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol (2005);46:CS5-6.
[7] Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al.
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama (2005);293:2126-30.
[8] Gawaz M. Das Blutplättchen. Stuttgart: Gawaz, Meinrad, 1999.
[9] Ruggeri ZM. Platelet and von Willebrand factor interactions at the vessel wall.
Hamostaseologie (2004);24:1-11.
[10] Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol (1997);29:91-105.
[12] Siess W. Molecular mechanisms of platelet activation. Physiol Rev (1989);69:58-178.
[13] Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy. Circulation (1999);99:E1-E11.
[14] Gawaz MP, Loftus JC, Bajt ML, Frojmovic MM, Plow EF, Ginsberg MH. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB-IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest (1991);88:1128-34.
[15] Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost (1995);74:352-9.
[16] Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost (1992);18:324-32.
[17] Bennett JS. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest (2005);115:3363-9.
[18] Critchley DR. Focal adhesions - the cytoskeletal connection. Curr Opin Cell Biol (2000);12:133-9.
[19] Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR et al. Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem (2002);277:46035-42.
[20] Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des (2006);12:1255-9.
[21] Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP et al. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.
Blood (1998);92:152-9.
[22] Mangin P, Ohlmann P, Eckly A, Cazenave JP, Lanza F, Gachet C. The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J Thromb Haemost (2004);2:969-77.
[23] Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM et al.
Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med (1999);5:1199-202.
[24] Cantley LC. The phosphoinositide 3-kinase pathway. Science (2002);296:1655-7.
[25] Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M et al.
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest (2003);112:398-406.
[26] Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE et al.
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest (2001);107:1591-8.
[27] Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V et al.
Identification of the platelet ADP receptor targeted by antithrombotic drugs.
Nature (2001);409:202-7.
[28] Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood (2002);99:193-8.
[29] Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol (2008);28:s33-8.
[30] Shankar H, Kahner B, Kunapuli SP. G-protein dependent platelet signaling--perspectives for therapy. Curr Drug Targets (2006);7:1253-63.
[31] Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy.
Nat Rev Drug Discov (2003);2:15-28.
[32] Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation (1999);100:1667-72.
[33] Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res (2006);99:1293-304.
[34] Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007);282:22254-66.
[35] Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J (2010);74:597-607.
[36] Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med (2007);357:2482-94.
[37] Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood (2002);100:148-52.
[38] Mann KG. Thrombin formation. Chest (2003);124:4S-10S.
[39] Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost (2002);88:186-93.
[40] Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol (1999);144:745-54.
[41] Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets.
Proc Natl Acad Sci U S A (1994);91:504-8.
[42] Hung DT, Wong YH, Vu TK, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem (1992);267:20831-4.
[43] Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S et al. A dual thrombin receptor system for platelet activation. Nature (1998);394:690-4.
[44] Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation (2006);114:1070-7.
[45] Langer H, Gawaz M. [The role of platelets for the pathophysiology of acute coronary syndromes]. Hamostaseologie (2006);26:114-8.
[46] Lindemann S, Kramer B, Daub K, Stellos K, Gawaz M. Molecular pathways used by platelets to initiate and accelerate atherogenesis. Curr Opin Lipidol (2007);18:566-73.
[47] Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res (2004);61:498-511.
[48] May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls.
Arterioscler Thromb Vasc Biol (2008);28:s5-10.
[49] Lindemann S, Kramer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost (2007);5 Suppl 1:203-11.
[50] Sami S, Willerson JT. Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 1). Tex Heart Inst J (2010);37:141-8.
[51] Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest (1989);84:18-27.
[52] Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med (1981);304:685-91.
[53] Willerson JT. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J (1995);22:13-9.
[54] Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth BG et al.
Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. Am J Cardiol (1984);54:1349-54.
[55] Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and
[56] Bounameaux Y. [Clinical use of anti-aggregative agents]. Bull Schweiz Akad Med Wiss (1973);29:223-34.
[57] Joyal D, Freihage JH, Cohoon K, Tempelhof M, Leya F, Dieter RS et al. The influence of low (81 mg) versus high (325 mg) doses of ASA on the incidence of sirolimus-eluting stent thrombosis. J Invasive Cardiol (2007);19:291-4.
[58] Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC et al.
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006);113:2363-72.
[59] Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest (1985);76:101-8.
[60] Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs (1994);48:583-98.
[61] Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998);97:1680-8.
[62] Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol (1995);76:1222-7.
[63] Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T et al.
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol (1996);27:536-42.
[64] De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.
J Am Coll Cardiol (2009);53:1668-73.
[65] Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008);358:2205-17.
[66] Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv (2009);2:230-6.
[67] Mehilli J, Kastrati A, Schulz S, Frungel S, Nekolla SG, Moshage W et al.
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading:
a randomized double-blind trial. Circulation (2009);119:1933-40.
[68] Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D et al.
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008);358:2218-30.
[69] Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA (2008);299:1788-99.
[70] Van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet (2008);372:537-46.
[71] Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman EM et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2009);54:2205-41.
[72] Karow T, Lang-Roth R. Thrombozytenaggregationshemmer. Pulheim: Karow, 2008.
[73] Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol (2001);52:333-6.
[74] Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR et al.
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000);342:1773-7.
[75] Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation (2007);115:2196-207.
[76] Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG et al.
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004);109:166-71.
[77] Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP et al.
Identification and biological activity of the active metabolite of clopidogrel.
Thromb Haemost (2000);84:891-6.
[78] Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol (2002);39:9-14.
[79] CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). . Lancet (1996);348:1329-39.
[80] Berger PB, Bell MR, Rihal CS, Ting H, Barsness G, Garratt K et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol (1999);34:1891-4.
[81] Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000);102:624-9.
[82] Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation (1999);99:2364-6.
[83] Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA et al.
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010);363:930-42.
[84] Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007);357:2001-15.
[85] Smith SC, Jr., Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ et al.
ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol (2001);37:2215-39.
[86] Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C et al.
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005);26:804-47.
[87] Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al.
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Lancet (2001);358:527-33.
[88] Van Giezen J, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost (2009);7:1556-65.
[89] Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol (2007);50:1844-51.
[90] James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H et al.
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2009);157:599-605.
[91] Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:
response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003);107:2908-13.
[92] Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res (2005);115:101-8.
[93] Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med (2002);252:233-8.
[94] Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost (2003);89:783-7.
[95] Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ.
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005);45:246-51.
[96] Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003);41:961-5.
[97] Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost (2007);5 Suppl 1:230-7.
[98] Seidel H, Rahman MM, Scharf RE. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie (2011);31:41-51.
[99] Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP et al.
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J (2008);29:992-1000.
[100] Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010);3:318-23.
[101] Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J et al.
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv (2010);3:35-40.
[102] Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J (2007);28:692-8.
[103] Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J (2006);27:2420-5.
[104] Reganon E, Vila V, Martinez-Sales V, Vaya A, Aznar J. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.
Haematologica (2002);87:740-5; discussion 745.
[105] Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res (2005);115:89-94.
[106] Lim E, Cornelissen J, Routledge T, Kirtland S, Charman SC, Bellm S et al.
Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial. J Thorac Cardiovasc Surg (2004);128:432-5.
[107] Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C et al.
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994);90:61-8.
[108] Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol (2000);36:1210-6.
[109] Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A et al.
Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation (1999);99:855-60.
[110] Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF et al.
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1999);33:634-9.
[111] Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.
Thromb Haemost (2006);96:781-8.
[112] Fox SC, Behan MW, Heptinstall S. Inhibition of ADP-induced intracellular Ca2+
responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium (2004);35:39-46.
[113] Sachs L. Angewandte Statistik. 10. Auflage. Berlin: Springer, 2002.
[114] Landis JR, Koch GG. The measurements of observer agreement for categorial data. Biometics (1977);33:671-679.
[115] Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res (2010);125:e190-6.
[116] Meier B, Bachmann D, Luscher T. 25 years of coronary angioplasty: almost a fairy tale. Lancet (2003);361:527.
[117] Yan Q, Changsheng M, Shaoping N, Xiaohui L, Junping K, Qiang L et al.
Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. Circ J (2009);73:1848-55.
[118] Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med (1979);301:61-8.
[119] Maisel WH. Unanswered questions--drug-eluting stents and the risk of late thrombosis. N Engl J Med (2007);356:981-4.
[120] Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI.
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004);126:576S-599S.
[121] Windecker S, Meier B. Late coronary stent thrombosis. Circulation (2007);116:1952-65.
[122] Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis (1997);8:121-8.
[123] Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007);28:1598-660.
[124] Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008);29:2909-45.
[125] Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R et al.
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol (2007);49:2312-7.
[126] Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M et al.
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol (2006);48:1742-50.
[127] Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008);336:195-8.
[128] Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C et al.
Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Circulation (2009);119:237-42.
[129] Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I et al.
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004);109:3171-5.
[130] Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol (2009);53:849-56.
[131] Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol (2006);47:27-33.
[132] Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol (2006);98:18N-24N.
[133] Fefer P, Hod H, Matetzky S. Clopidogrel resistance--the cardiologist's perspective. Platelets (2007);18:175-81.
[134] Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B et al.
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart (2008);94:743-7.
[135] Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H et al.
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA (2006);295:1531-8.
[136] von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J (2007);28:1814-9.
[137] Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB et al.
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J (2008);156:1080-1088 e1.
[138] Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB et al.
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010);376:1233-43.
[139] Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP et al.
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2009);30:655-61.
[140] Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol (2007);100:1364-9.
[141] Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol (2007);49:1362-8.
[142] Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A et al.
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008);51:690-7.
[143] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009);361:1045-57.
[144] Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol (2008);52:1052-9.
[145] Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting.
Platelets (2009);20:97-104.
[146] Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol (2003);41:966-8.
[147] von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W et al.
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coagul Fibrinolysis (2010);21:46-52.
[148] Awidi A, Maqablah A, Dweik M, Bsoul N, Abu-Khader A. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Platelets (2009);20:297-301.
[149] Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A et al.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2009);30:426-35.
[150] Siller-Matula JM, Gouya G, Wolzt M, Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost (2009);102:397-403.
[151] Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV.
Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med (2007);167:1593-9.